ArticleCureus2025
C-peptide Trajectory Following Pancreas Transplantation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreas transplantation is the most reliable management of insulin-dependent diabetes mellitus, offering sustained glycemic control with a reduction in diabetes-related complications. Despite recent advancements, recipient selection criteria are not standardized. Historically, pre-transplant C-peptide level was an important indicator of post-transplant success, yet conflicting data exist regarding their correlation. This study explores post-transplant C-peptide trends in recipients with varying pre-transplant C-peptide levels, aiming to elucidate its impact on patient and graft survival.
methodsA retrospective review of 78 pancreas transplant recipients (simultaneous pancreas and kidney, pancreas after kidney, and pancreas transplant alone) from September 2012 to August 2022 was conducted. Patients were categorized based on pre-transplant C-peptide levels (>4.0 ng/mL elevated vs. ≤4.0 ng/mL low/normal). C-peptide levels, HbA1c, and estimated glomerular filtration rate (eGFR) were monitored at specified intervals post-transplant.
resultsThe two cohorts exhibited disparate post-transplant C-peptide trends; elevated (pre-transplant: mean = 8.43 ng/mL, range = 4-28.26 ng/mL; post-transplant: mean = 3.57 ng/mL, range = 0.84-8.53 ng/mL) and low/normal (pre-transplant: mean = 1.07 ng/mL, range = 0-3.92 ng/mL; post-transplant: mean = 2.81 ng/mL, range = 0.9-6.73 ng/mL). Despite achieving normoglycemic control (HbA1c 5.26% and 5.19%, respectively), the decline in C-peptide levels in the elevated pre-transplant group contradicted the anticipated outcomes.
conclusionThis study highlights the intricate dynamics of post-transplant C-peptide, revealing unexpected patterns in recipients with elevated pre-transplant C-peptide levels. The study's findings question the predictive value of pre-transplant C-peptide levels and underscore the importance of further research to unravel its metabolism post-transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.